The overall goal of the Experimental Therapeutics (ET) Program is the development of novel mechanism-driven anticancer therapies through an improved understanding of molecular pathways in normal cells and cancer cells and insights into mechanisms involved in drug resistance. To achieve this goal, the Program is organized into three interacting (interactive) research themes that span the spectrum of basic, translational and clinical science: Angiogenesis and Metastasis, Cell Survival and Drug Resistance, and Gene expression and Molecular Targets, In addition to these themes, the ET program has two overarching missions. First, to be the conduit for bringing scientific findings from other CCSG programs into the clinic. As such, the Phase I and ET Drug Development expertise provides an Institute-wide resource for drug discovery methods, preclinical efficacy studies, IND-enabling toxicology, IND submission support, PK/PD modeling, and clinical trial conduct and management. Secondly, the ET Program is committed to training the next generation of clinician-scientists with expertise in all phases of drug development. The Program is co-led by Drs. Alex Adjei, and William Cance. Dr. Adjei is an internationally recognized clinician scientist with expertise in drug development, phase l/ll clinical trials of novel cancer agents and lung cancer. As the director of the Phase I unit, his leadership has been instrumental in building the drug development team. His research interests are in targeting cell survival pathways for cancer therapy in lung cancer. Dr. Cance is a highly regarded cancer surgeon and translational scientist with long-standing interests in angiogenesis and tumor metastasis. He has an ROl-funded program evaluating FAK inhibitors for cancer therapy. The complementary expertise of the leadership team facilitates the integration of basic, translational and clinical science by providing venues to promote discussion of research, formation of basic science-clinical partnerships, and providing guidance to membership for available research funding. The Program consists of 25 members from 7 departments. 541 publications are the product of ET members (2008-2013), with 23% of the publications as intra-programmatic and 22% inter-programmatic. 34 publications were in journals with Impact Factor >10. The ET Program has translated recent preclinical findings into 12 ongoing clinical trials. There were 326 patients enrolled to treatment trials in CY2012 compared with 453 patients in CY2008. Current annual total peer-reviewed Program funding is $10.3M, of which $9.3M is from NCI, and the total extramural research funding is $14.4M.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016056-37
Application #
8738361
Study Section
Subcommittee G - Education (NCI)
Project Start
1997-06-16
Project End
2019-04-30
Budget Start
2014-06-26
Budget End
2015-04-30
Support Year
37
Fiscal Year
2014
Total Cost
$39,194
Indirect Cost
$15,503
Name
Roswell Park Cancer Institute Corp
Department
Type
DUNS #
824771034
City
Buffalo
State
NY
Country
United States
Zip Code
14263
Eng, Diana G; Kaverina, Natalya V; Schneider, Remington R S et al. (2018) Detection of renin lineage cell transdifferentiation to podocytes in the kidney glomerulus with dual lineage tracing. Kidney Int 93:1240-1246
Ling, Xiang; Wu, Wenjie; Fan, Chuandong et al. (2018) An ABCG2 non-substrate anticancer agent FL118 targets drug-resistant cancer stem-like cells and overcomes treatment resistance of human pancreatic cancer. J Exp Clin Cancer Res 37:240
Chung, Sejin; Vail, Paris J; Witkiewicz, Agnieszka K et al. (2018) Coordinately targeting cell cycle checkpoint functions in integrated models of pancreatic cancer. Clin Cancer Res :
Mohammadpour, Hemn; O'Neil, Rachel; Qiu, Jingxin et al. (2018) Blockade of Host ?2-Adrenergic Receptor Enhances Graft-versus-Tumor Effect through Modulating APCs. J Immunol 200:2479-2488
Hsu, Alice H; Lum, Michelle A; Shim, Kang-Sup et al. (2018) Crosstalk between PKC? and PI3K/AKT Signaling Is Tumor Suppressive in the Endometrium. Cell Rep 24:655-669
Sandlesh, Poorva; Juang, Thierry; Safina, Alfiya et al. (2018) Uncovering the fine print of the CreERT2-LoxP system while generating a conditional knockout mouse model of Ssrp1 gene. PLoS One 13:e0199785
Zhang, Dingxiao; Zhao, Shuhong; Li, Xinyun et al. (2018) Prostate Luminal Progenitor Cells in Development and Cancer. Trends Cancer 4:769-783
Hong, Chi-Chen; Sucheston-Campbell, Lara E; Liu, Song et al. (2018) Genetic Variants in Immune-Related Pathways and Breast Cancer Risk in African American Women in the AMBER Consortium. Cancer Epidemiol Biomarkers Prev 27:321-330
Damayanti, Nur P; Budka, Justin A; Khella, Heba W Z et al. (2018) Therapeutic Targeting of TFE3/IRS-1/PI3K/mTOR Axis in Translocation Renal Cell Carcinoma. Clin Cancer Res 24:5977-5989
Mayor, Paul; Starbuck, Kristen; Zsiros, Emese (2018) Adoptive cell transfer using autologous tumor infiltrating lymphocytes in gynecologic malignancies. Gynecol Oncol 150:361-369

Showing the most recent 10 out of 1555 publications